The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacological preconditioning with resveratrol: role of nitric oxide
Abstract
Resveratrol ( trans-3,4′,5-trihydroxystilbene), a recently described grape-derived polyphenolic antioxidant, has been found to protect the heart from ischemic-reperfusion injury. The present study sought to determine the mechanism of cardioprotection by investigating the ability of resveratrol to precondition the heart. Isolated perfused rat hearts were randomly divided into six groups: group Iwas perfused for 15 min with Kreb-Henseleit buffer (KHB) only; group II was perfused with 10 μM resveratrol; group III was perfused with 10 μM resveratrol plus 100 μM N G -nitro-l-arginine methyl ester (l-NAME), a nonselective nitric oxide (NO) synthase (NOS) inhibitor; group IV was perfused with 10 μM resveratrol plus 100 μM aminoguanidine (AG), an inducible NOS (iNOS) blocker; and groups V and VI consisted of hearts perfused withl-NAME and AG, respectively. The perfusion was then switched to working mode, and all hearts were made globally ischemic for 30 min followed by 2 h of reperfusion. Preconditioning of the hearts with resveratrol provided cardioprotection as evidenced by improved postischemic ventricular functional recovery (developed pressure and aortic flow) and reduced myocardial infarct size and cardiomyocyte apoptosis. Resveratrol-mediated cardioprotection was completely abolished by both l-NAME and AG. In a separate study, hearts were examined for iNOS mRNA induction. Resveratrol caused an induction of the expression of iNOS mRNA beginning at 30 min after reperfusion, increasing steadily up to 60 min of reperfusion, and then decreasing progressively up to 2 h after reperfusion. Preperfusion of the hearts with AG almost completely blocked the induction of iNOS. The results of our study demonstrate that resveratrol can pharmacologically precondition the heart in a NO-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 1×
“For example, both resveratrol and NO possess anti-inflammatory and antiplatelet activities (21, 23) and can exert vasodilatory effects on blood vessels (29).”
Background
Cited by
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Regulation of inflammation and redox signaling by dietary polyphenols
Rahman, I., Biswas, S. K., & Kirkham, P. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.07.004 · Cited by 991
Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications
de la Lastra, C. A., & Villegas, I. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351156 · Cited by 740
Cardiovascular Protective Effects of Resveratrol
Bradamante, S., Barenghi, L., & Villa, A. (2004) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2004.tb00139.x · Cited by 528
Resveratrol: from grapevines to mammalian biology
Pervaiz, S. (2003) · The FASEB Journal · doi:10.1096/fj.03-0168rev · Cited by 520
Metadata
- Authors
- Hattori, R., Otani, H., Maulik, N., & Das, D. K.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2002-06-01
- Volume
- 282
- Issue
- 6
- Pages
- H1988-H1995
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2130345110
- Cited by
- 202
- References
- 1
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.